O
AERI

OrbiMed’s Aerie Pharmaceuticals AERI Stock Holding History

OrbiMed’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-58,000
Closed -$2.75M – 141
2019
Q1 		$2.75M Sell
58,000
-814,100
-93% -$35.8M 0.04% 114
2018
Q4 		$31.5M Sell
872,100
-347,730
-29% -$16.3M 0.58% 54
2018
Q3 		$75.1M Sell
1,219,830
-664,270
-35% -$42.7M 0.9% 32
2018
Q2 		$127M Hold
1,884,100
– – 1.52% 17
2018
Q1 		$102M Buy
1,884,100
+554,500
+42% +$31M 1.27% 26
2017
Q4 		$79.4M Sell
1,329,600
-108,582
-8% -$6.58M 1% 33
2017
Q3 		$69.9M Sell
1,438,182
-393,465
-21% -$21.5M 0.67% 44
2017
Q2 		$96.3M Buy
1,831,647
+335,647
+22% +$15.6M 1.01% 28
2017
Q1 		$67.8M Hold
1,496,000
– – 0.77% 42
2016
Q4 		$56.6M Buy
1,496,000
+698,900
+88% +$26.4M 0.72% 41
2016
Q3 		$30.1M Buy
+797,100
New +$17.6M 0.34% 63

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

OrbiMed's AERI Position: Q2 2019 in Review

OrbiMed sold out of Aerie Pharmaceuticals (AERI) in Q2 2019, closing a stake of 58,000 shares — an estimated $2.75M sold.

OrbiMed first reported a position in AERI in Q3 2016 and held it in 11 quarters. The position peaked at $127M in Q2 2018. 167 funds tracked by Wall St. Rank hold AERI as of Q2 2019.

  • OrbiMed reported no remaining Aerie Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • OrbiMed sold 58,000 Aerie Pharmaceuticals shares in Q2 2019, an estimated $2.75M.
  • OrbiMed first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 11 quarters.
  • OrbiMed's Aerie Pharmaceuticals position peaked at $127M in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2019.

Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.